Skip to main content
MyDeficiencies

Dulaglutide

GLP-1 Receptor Agonist

Also sold as Trulicity.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Dulaglutide is a large fusion-protein peptide that is not metabolized by CYP450 enzymes, induces no hepatic enzymes, and is not cleared renally as intact drug; it is presumed to be catabolized to amino acids by general protein-breakdown pathways, the same way the body handles dietary protein. This gives it none of the classical depletion machinery seen with enzyme-inducing anticonvulsants, loop diuretics, or acid-suppressing drugs. There is no chelation, no renal tubular wasting, and no CYP-mediated cofactor loss. The one mechanism this drug plainly has is reduced intake: nausea (21%), vomiting (13%), diarrhea (13%), abdominal pain (9%), and decreased appetite (9%) are common, dose-related adverse effects documented in the FDA label, and severe gastrointestinal reactions with dehydration have produced postmarketing reports of acute kidney injury, in some cases requiring hemodialysis.

GLP-1 receptor agonist · ATC A10BJ05 · also sold as Trulicity · reviewed 2026-09-20. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Dulaglutide in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: two or more independent Tier A sources with this drug in the studied cohort, the nutrient directly measured, consistent direction and clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: at least one Tier A source with this drug in the cohort showing a real, bounded effect (exposure window, subgroup, low frequency, or functional rather than circulating measure). Boundary stated in the title.
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective signals.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. A disclosed gap in the literature or in what this review could access, never reworded as reassurance.

What the research found

Thiamine

Yellow — Low

See study details

Wernicke encephalopathy and other thiamine-deficiency presentations have been reported with GLP-1 receptor agonists, but every case-level source identified names semaglutide specifically; dulaglutide shares the class mechanism (severe GI intolerance, appetite loss) at a generally lower intensity.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective signals. yellow

Limits on what this shows

  • Key negative/null findings: None identified; absence of dulaglutide-named cases may reflect dulaglutide's typically smaller weight-loss effect at diabetes dosing versus semaglutide, lower case volume, or simply that no case has yet been published or indexed.
  • At-risk subgroups: Patients with prolonged, severe vomiting or very low intake after dose escalation; pre-existing malnutrition, alcohol use, or bariatric surgery history would compound risk.
  • Counter-evidence on record: This is class extrapolation (Tier C for dulaglutide): the class member with real data (semaglutide) is not dulaglutide, and confounding by indication/severity of illness in case reports has not been excluded.

Regulatory status

Not addressed in the dulaglutide label beyond the general dehydration/AKI warning tied to GI adverse reactions.

Population evidence

Multiple 2025-2026 case reports and reviews describe Wernicke encephalopathy, axonal neuropathy, and lumbosacral polyradiculopathy attributed to micronutrient deficiency after GLP-1 agonist use, all naming semaglutide in the titles identified (e.g., "Semaglutide-induced Wernicke encephalopathy," "Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy," "Severe lumbosacral polyradiculopathy secondary to micronutrient deficiencies in a patient on semaglutide therapy"). No dulaglutide-named case was identified in this review.

Mechanism

Present and named: severe, prolonged vomiting and markedly reduced intake (mechanism class H) can precipitate thiamine deficiency, since thiamine stores are small and rapidly depleted. Dulaglutide carries the same GI adverse-effect profile in its own label (nausea 21%, vomiting 13%, severe GI reactions 4.3% at the 1.5 mg dose) and its own AKI-from-dehydration warning, so the mechanism is plausible for this drug, just not yet documented in a dulaglutide-named case.

Counter-evidence held on record

This is a monitoring prompt for severe, prolonged vomiting, not a routine supplementation recommendation. No dose is given here (see Scope and Limits); any suspected thiamine deficiency requires clinical evaluation, not self-directed supplementation.

Vitamin D / calcium / bone density

Not graded — disclosed evidence gap

See study details

Vitamin D / calcium / bone density

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: A direct PubMed search for dulaglutide combined with bone mineral density, calcium, and vitamin D returned zero results, and no dulaglutide-specific or class-level circulating claim on this axis was identified in the literature reviewed (unlike, for example, the well-known PPI-fracture or loop-diuretic-calciuria narratives). This is treated as a genuine literature gap, not as reassurance that no effect exists.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

One dulaglutide-named cardiac study title reports prevention of diabetic metabolic/mitochondrial remodeling; the species and study design could not be independently verified from the abstract text this review could access.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective signals. yellow

Limits on what this shows

  • Key negative/null findings: None identified; only one source found.
  • At-risk subgroups: Not established from available data.
  • Counter-evidence on record: A second title matching "dulaglutide" and "mitochondria" concerned synoviocyte inflammation, not mitochondrial structure/function, and was not used as supporting evidence here.

Regulatory status

Not addressed in the label.

Population evidence

"Long-Term Activation of Glucagon-like Peptide-1 Receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes" (J Am Heart Assoc, 2022, PMID 36172969) reports a protective, not depleting, direction. This review could confirm the title, journal, and year through PubMed's search-listing page, but could not open the full abstract to confirm the species/model (the study is presumed preclinical given the depth of tissue-level "metabolic remodeling" assessment typical of this literature, but this is not independently verified here).

Mechanism

Named in the title only as prevention of "metabolic remodeling" in a diabetic heart-failure context; specific mitochondrial structural or electron-transport-chain detail not confirmed.

Counter-evidence held on record

Single-source, verification-limited finding in the protective direction. Not a basis for any consumer-facing claim about mitochondrial support; flagged for follow-up verification when full-text access is available.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

Direction: reduced (reverse-direction) · Evidence in: Tier A, human

Two prospective, dulaglutide-specific human trials measured oxidative-stress markers on dulaglutide: one found no significant between-group difference versus liraglutide, and the other found that switching to semaglutide was superior to continuing dulaglutide. No placebo arm establishes any dulaglutide effect against no treatment, and comparator superiority does not quantify a dulaglutide effect.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective signals. YELLOW · Direction: reduced (reverse-direction) · Tier A, human, active-comparator only · revised 2026-09-23 after QA re-reading of PMID 30612316 and PMID 37880502

Limits on what this shows

  • Key negative/null findings: Nagaike et al. 2019 (PMID 30612316) reported no significant between-group change in diacron-reactive oxygen metabolites between dulaglutide and liraglutide — a null between-group oxidative-stress result for dulaglutide. Omachi et al. 2024 (PMID 37880502) reports comparator superiority for semaglutide rather than a quantified dulaglutide effect. Both studies were active-comparator designs (drug versus drug), so neither establishes the effect against a true no-treatment baseline.
  • At-risk subgroups: Not established; both source studies were general T2DM adult populations.
  • Counter-evidence on record: Active-comparator design in both trials means the reduction could partly reflect glycemic improvement itself (confounding by improved control) rather than a drug-specific antioxidant mechanism; this has not been excluded.

Regulatory status

Not addressed in the FDA label; this is an off-target pharmacodynamic finding from independent clinical research, not a labeled effect.

Population evidence

Nagaike et al. 2019, prospective study of dulaglutide versus liraglutide in T2DM patients, measured oxidative stress and endothelial function; dulaglutide showed effects "comparable" to liraglutide. Omachi et al. 2024, prospective preliminary study using continuous glucose monitoring, compared injectable semaglutide and dulaglutide on oxidative stress and glucose variability; switching to semaglutide showed superior results versus continuing dulaglutide; superiority of the comparator says nothing about the size of any dulaglutide effect, and no smaller-but-real dulaglutide benefit is inferred from it. Exact effect sizes and confidence intervals could not be independently confirmed from accessible abstract text (see access notes).

Mechanism

Not fully elucidated in the sources found; proposed via improved glycemic variability and possible direct anti-inflammatory/endothelial effects of GLP-1 receptor activation, not a nutrient-cofactor mechanism.

Counter-evidence held on record

This is a favorable, reverse-direction signal, not a deficiency. It should never be presented as evidence that dulaglutide is an antioxidant therapy, and it is not grounds for recommending antioxidant supplements to patients on dulaglutide; the effect has not been confirmed against a no-treatment control.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron

Yellow — Low

See study details

A pediatric GLP-1 receptor agonist cohort study reported iron-deficiency anemia in 1.44% of patients within one year of treatment; the drug composition of that cohort could not be confirmed to include dulaglutide by name, and no dulaglutide-specific iron study was found.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective signals. yellow

Limits on what this shows

  • Key negative/null findings: None identified specific to dulaglutide; a direct PubMed search combining dulaglutide with iron, copper, and trace element terms returned zero results.
  • At-risk subgroups: Pediatric patients (dulaglutide is approved for youth type 2 diabetes ages 10 and up) and any patient with prolonged reduced intake or heavy menstrual losses.
  • Counter-evidence on record: Confounding by indication is not excluded: obesity and type 2 diabetes populations can carry baseline iron-deficiency prevalence independent of GLP-1 therapy, and the cited study's drug composition could not be verified as including dulaglutide.

Regulatory status

Not addressed in the dulaglutide label.

Population evidence

"Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists" (Child Obes, 2026) reports iron-deficiency anemia incidence of 1.44% in pediatric patients on GLP-1 receptor agonists within one year; the abstract text accessible to this review discussed GLP-1RAs as a class without naming dulaglutide specifically among the agents studied.

Mechanism

Present: reduced dietary intake from appetite suppression and GI adverse effects (mechanism class H), which is well documented for dulaglutide itself in its own label, is a plausible route to iron-deficiency anemia over time, independent of any drug-specific molecular mechanism.

Counter-evidence held on record

A monitoring flag for patients with sustained poor intake, not a supplementation recommendation. No dose is given (see Scope and Limits).

Copper

Not graded — disclosed evidence gap

See study details

Copper

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence was found linking dulaglutide, or the GLP-1 receptor agonist class generally, to copper status, and no circulating consumer claim about dulaglutide and copper was identified to rebut. PubMed searches combining dulaglutide with copper, iron, and trace-element terms, and combining the GLP-1 receptor agonist class with copper, iron, or zinc, returned no relevant matches. Europe PMC and Semantic Scholar API access were blocked by gateway policy throughout this review (see access notes), so cross-verification on those channels was not possible; a later revision should re-check this category when those channels are reachable.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Yellow — Low

See study details

A dulaglutide-specific randomized pilot trial included exploratory microbiome analysis, and a separate trial tested dulaglutide plus probiotics against dulaglutide alone; neither the specific direction of dulaglutide's microbiome effect nor its magnitude could be confirmed from accessible abstract text.

Full detail, limits and 3 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective signals. yellow

Limits on what this shows

  • Key negative/null findings: Not accessible from the sources found.
  • At-risk subgroups: Not established from available data.
  • Counter-evidence on record: A 2025 systematic review, "Effects of GLP-1 Analogues and Agonists on the Gut Microbiota" (PMID 40284168), exists at the class level, but this review could not confirm whether dulaglutide-specific studies were among those it stratified, so it is treated as Tier C context only, not independent confirmation.

Regulatory status

Not addressed in the label.

Population evidence

Jun JE et al., "Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses" (2026, PMID 42388875), confirms dulaglutide was studied with microbiome endpoints, but this review could not open the full abstract to report direction or magnitude. Tian J et al., "Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM" (2025, PMID 40214965), used a probiotic add-on design implying an assumed microbiome-modulating rationale rather than directly reporting dulaglutide's own microbiome effect.

Mechanism

Plausible via delayed gastric emptying and altered nutrient delivery timing to the colon (mechanism class A), a class-wide property of GLP-1 receptor agonists documented for dulaglutide in its own label.

Counter-evidence held on record

Investigation exists; direction and clinical significance do not. This should not be presented to consumers as either a risk or a benefit until the underlying findings can be verified.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

Oxygen delivery/utilization

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence of an effect on hemoglobin, hematocrit, red-cell mass, or arterial oxygenation was found, and no circulating claim was identified to rebut. Multiple PubMed phrasings were tried ("dulaglutide hemoglobin hematocrit erythropoiesis oxygen," "dulaglutide hematocrit," "dulaglutide hemoglobin level"); results returned were almost entirely about glycated hemoglobin (HbA1c), the drug's own intended glycemic-control marker, not true oxygen-carrying hemoglobin, and this distinction is deliberately not conflated here per the hard rule against filing a drug's own intended pharmacologic effect as a nutrient/category finding. Europe PMC and Semantic Scholar access were blocked this session (see access notes).

ATP production

Not graded — disclosed evidence gap

See study details

ATP production

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: No Tier B or Tier C evidence was found for dulaglutide or the GLP-1 receptor agonist class on ATP synthesis or cellular energy output specifically, and no distinct circulating "ATP depletion" claim (as opposed to the drug's documented, separately-tracked adverse effect of fatigue/asthenia) was identified. Two PubMed phrasings ("dulaglutide ATP energy metabolism mitochondrial biogenesis" and "GLP-1 receptor agonist ATP production OXPHOS cellular respiration") returned zero results. Europe PMC and Semantic Scholar access were blocked this session (see access notes); this category should be re-checked in a future revision when those channels are reachable.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Vitamin B12

    Where it comes from: General "diabetes medication depletes B12" consumer narrative, which typically originates from metformin's well-documented ileal-transporter/intrinsic-factor interaction and is loosely applied to any injectable diabetes drug taken alongside it, including dulaglutide.

    Why it fails: Dulaglutide has no acid-suppressing, no intrinsic-factor, and no ileal-transporter mechanism; a direct PubMed search for dulaglutide combined with vitamin B12 or cobalamin returned zero results, and no other GLP-1 receptor agonist was found with drug-level B12 evidence either. The real, well-established B12 risk in this patient population is metformin, which is very frequently co-prescribed with dulaglutide; conflating the two drugs is the specific error this entry rebuts.

All references used above
  1. TRULICITY (dulaglutide) injection, full prescribing information. — Eli Lilly and Company / DailyMed, FDA label, accessed via DailyMed setid 463050bd-2b1c-40f5-b3c3-0a04bb433309.
  2. TRULICITY (dulaglutide) injection, USPI PDF. — Eli Lilly and Company, current prescribing information.
  3. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code A10BJ05. — Reference for ATC classification and defined daily dose.
  4. Omachi T, et al. Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study. — Diabetes Therapy, 2024. PMID 37880502. Dulaglutide in cohort (switch-comparator design).Full abstract text could not be opened by this review's tooling; graded from title, journal, and search-listing snippet only.
  5. Nagaike H, et al. Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study. — Diabetes Therapy, 2019. PMID 30612316. Dulaglutide in cohort (active-comparator design).Full abstract text could not be opened by this review's tooling; graded from title, journal, and search-listing snippet only.
  6. Xie S, et al. Long-Term Activation of Glucagon-like Peptide-1 Receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes. — Journal of the American Heart Association, 2022. PMID 36172969. Dulaglutide named in title; species/model not independently confirmed by this review.Full abstract text could not be opened by this review's tooling.
  7. Jun JE, et al. Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses. — 2026. PMID 42388875. Dulaglutide in cohort.Full abstract text could not be opened by this review's tooling; direction/magnitude of microbiome findings not confirmed.
  8. Tian J, et al. Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM. — 2025. PMID 40214965. Dulaglutide in cohort.Full abstract text could not be opened by this review's tooling.
  9. Gofron KK, Wasilewski A, Malgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. — 2025. PMID 40284168. Class-level systematic review; whether dulaglutide-specific studies were included among the stratified results could not be confirmed by this review.Class-level source (Tier C for dulaglutide); full text not opened.
  10. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. — 2026. PMID 41549912. Search-listing snippet named semaglutide and liraglutide specifically; dulaglutide not indicated as included.Cohort excluded dulaglutide by name in the accessible snippet; Tier C class-level context only.
  11. Simancas-Racines D, et al. Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework. — Obesity Pillars, 2026. PMID 42382663. Class-level narrative review.Full text not opened; drug-level stratification not confirmed. Tier C context only, not used to support any graded entry above yellow.
  12. Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists. — Child Obesity, 2026. PMID 42751742. Reports iron-deficiency anemia in 1.44% of pediatric patients; accessible snippet discussed GLP-1RAs as a class without confirming dulaglutide by name among agents studied.Drug composition of cohort not confirmed to include dulaglutide; treated as Tier C class-level signal only.
  13. Representative semaglutide-specific thiamine/Wernicke encephalopathy case literature: "Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis" (PMID 40908328); "Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy" (PMID 41534460); "Severe lumbosacral polyradiculopathy secondary to micronutrient deficiencies in a patient on semaglutide therapy" (PMID 40956288). — 2025-2026, case reports/reviews. Semaglutide named specifically in each; dulaglutide not named in any case identified.Cohort/case is semaglutide, not dulaglutide; used only to establish class-level plausibility (Tier C) for the thiamine entry, per the mandatory cohort test.
  14. Dulaglutide-specific body composition studies: "Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment" (PMID 38505539, 2024); "The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis" (PMID 29937137, 2018). — Dulaglutide in cohort; used for monitoring-panel context on lean-mass change, not graded as a nutrient-deficiency entry per Hard Rule 2.Full abstract text not opened; title/snippet-level use only.